TrialBMJ open diabetes research & care2021

Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.

Samuel Dagogo-Jack et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.